<DOC>
	<DOCNO>NCT02410733</DOCNO>
	<brief_summary>The purpose study determine safety tolerability intravenous administration tetravalent RNA-lipoplex cancer vaccine target four tumor-associated antigen patient advance melanoma .</brief_summary>
	<brief_title>Evaluation Safety Tolerability i.v . Administration Cancer Vaccine Patients With Advanced Melanoma</brief_title>
	<detailed_description>- The Lipo-MERIT vaccine consist four naked ribonucleic acid ( RNA ) -drug product ( DPs ) RBL001.1 , RBL002.2 , RBL003.1 , RBL004.1 optimise induce antigen-specific CD8+ CD4+ T cell response four select malignant melanoma-associated antigen respectively . - In study , naked RNA DPs formulate liposome form RNA-lipoplexes ( RNA ( LIP ) ) ( ) protect RNA degradation serum , ( ii ) enable vivo target systemic antigen-presenting cell ( APC ) , therefore ( iii ) constitute novel vaccine formulation support intravenous administration . - The Lipo-MERIT vaccine expect lead several effect contribute immunological ( therapeutic ) effect . First , RNA-lipoplexes home APCs lymphoid organ intravenous injection , rapidly take professional APCs . Incorporated RNA translocate cytoplasm lead translation host ribosome complex four Antigen encode protein process presented HLA-class I well HLA-class II molecule . Consecutively , antigen-specific CD8+ CD4+ T cell response trigger HLA-peptide complex surface antigen-presenting cell . - In addition , Lipo-MERIT vaccine expect transiently activate APCs ( change surface marker expression cytokine secretion ) via signal TLRs , subsequently lead transient induction inflammatory cytokine ( IFN-α IP-10 ) support induction tumour-antigen specific T cell response .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Cohort I : stage IV malignant melanoma ( AJCC 2009 melanoma classification ) Cohorts IIV : stage IIIBC , stage IV malignant melanoma ( AJCC 2009 melanoma classification ) Therapy subject eligible decline available approved therapy available treatment option transparently disclose ( documented ! ) Expression either one four TAA confirm RTqPCR analysis FFPE ≥ 18 year age Written inform consent ECOG performance status ( PS ) 01 Life expectancy &gt; 6 month WBC ≥ 3x10E9/L Hemoglobin ≥ 10 g/dL Platelet count ≥ 100,000/mm³ LDH level &lt; 2.0 x ULN ALT/AST &lt; 3 x ULN ( except patient liver metastasis ) Negative pregnancy test ( measure βHCG ) females childbearing age Pregnancy breastfeed Primary ocular melanoma Concurrence second malignancy squamous basal cell carcinoma , nonactive prostate cancer cervical carcinoma situ nonactive treat urothelial carcinoma Brain metastasis Postsplenectomy patient Known symptomatic pleural effusion and/or ascites Known hypersensitivity active substance excipients A serious local infection ( e. g. cellulitis , abscess ) systemic infection ( e. g. pneumonia , septicemia ) require systemic antibiotic treatment within 2 week prior first dose study medication Positive test acute chronic active hepatitis B C infection Clinically relevant autoimmune disease Systemic immune suppression : HIV disease Use chronic oral systemic steroid medication ( topical inhalational steroid permit ) Other clinical relevant systemic immune suppression Symptomatic congestive heart failure ( NYHA 3 4 ) Unstable angina pectoris Radiotherapy minor surgery within 14 day prior first administration study treatment Myelosuppressive chemotherapy within 14 day reconstitution blood value prior first administration study treatment Ipilimumab within 28 day prior first administration study treatment Interferon , major surgery , vaccination , investigational agent within 28 day 5 halflifes depend give long range first treatment Approved BRAF inhibitor Vemurafenib Dabrafenib , approve antiPD1 antibody Opdivo Keytruda well approve MEK inhibitor Trametinib patient dose escalation cohort . Concomitant treatment approve BRAF Inhibitors , approve antiPD1 antibody MEK inhibitor well approve combination BRAFMEK inhibitor allow patient include expanded cohort , analysis safety data collect dose escalation cohort DSMB approval . Local radiation allow concurrent treatment . Fertile male female unwilling use highly effective method birth control ( le 1 % per year , e.g . condom spermicide , diaphragm spermicide , birth control pill , injection , patch intrauterine device ) study treatment 28 day last dose study treatment Presence serious concurrent illness condition ( e. g. psychological , family , sociological , geographical circumstance ) permit adequate followup compliance protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>melanoma</keyword>
	<keyword>Lipo-MERIT</keyword>
	<keyword>cancer vaccine</keyword>
	<keyword>RB_0003-01</keyword>
	<keyword>BioNTech</keyword>
	<keyword>BioNTech RNA Pharmaceuticals</keyword>
	<keyword>BioNTech RNA</keyword>
	<keyword>RNA</keyword>
</DOC>